# Kaiser Washington Vaccine and Treatment Evaluation Unit

> **NIH NIH UM1** · KAISER FOUNDATION RESEARCH INSTITUTE · 2021 · $415,583

## Abstract

Abstract
Infectious diseases continue to pose a significant threat to human health, with many types of infections having
far-reaching, global consequences. The ability to develop vaccines, therapeutics, devices and diagnostics to
prevent, treat, and identify infectious diseases is a critical public health need. Clinical trials are an integral
component of these development efforts. Since the 1960s the Vaccine and Treatment Evaluation Units
(VTEUs) have conducted trials that have evaluated promising vaccine and therapeutic candidates for infectious
diseases such as influenza (including pandemic and avian influenza), malaria, tuberculosis, pneumococcal
infection, in children and adults. In addition, the VTEUs have quickly launched trials in response to newly
emerging and reemerging infectious diseases, such as the 2009 influenza H1N1 pandemic, and Waves 1 and
5 of the H7N9 avian influenza outbreaks in China. These efforts have provided data that informed public health
policy.
This proposal is in response to a new VTEU structure which will involve greater collaboration between the
VTEUs, NIAID, and the newly formed Leadership Group structure that are all part of the NIAID Infectious
Diseases Clinical Research Consortium (IDCRC). The IDCRC will enhance integration and efficiency of
operations and, importantly, will foster the collaborative team science approaches now recognized as optimal
to address important and complicated public health research priorities.
Under the new cooperative agreement, the Kaiser Washington VTEU will continue to conduct clinical research
and trials, including trials conducted under an IND or IDE, within the Kaiser Washington integrated care system
to contribute to the priority research foci of NIAID. These priority areas include malaria, influenza and other
respiratory infections, acute respiratory infections and include clinical trials, including human challenge models,
and pharmacokinetic studies. The research will be conducted in collaboration with Seattle area infectious
disease research partners who will provide scientific expertise, specialized facilities, and advanced
immunologic laboratory capabilities. The Kaiser Washington VTEU will also develop and maintain surge
capacity for clinical site, pharmacy and laboratory operations to enable the rapid initiation of clinical trials and
other studies in response to emerging and reemerging infectious disease threats of public health importance.

## Key facts

- **NIH application ID:** 10403145
- **Project number:** 3UM1AI148373-02S4
- **Recipient organization:** KAISER FOUNDATION RESEARCH INSTITUTE
- **Principal Investigator:** LISA A JACKSON
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $415,583
- **Award type:** 3
- **Project period:** 2021-06-11 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10403145

## Citation

> US National Institutes of Health, RePORTER application 10403145, Kaiser Washington Vaccine and Treatment Evaluation Unit (3UM1AI148373-02S4). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10403145. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*